Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MAP-AD

Financiado

Cerrado

A Methylation Profiling Diagnostic for Early Diagnosis of Alzheimer s disease

Each year an estimated 40M people suffer from Alzheimer’s disease (AD) globally, and a new case is diagnosed every 4 seconds, leading to a substantial socioeconomic burden of over €800B annually. Despite this large need, currently... ver más

31/03/2024

ADMIT THERAPEUTICS

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ADMIT THERAPEUTICS Como actividad principal cnae 7211 investigacion y desarrollo experimental en biotecnologia. desarrollo de actividades de investigacion e in...

TRL 3-4 | 371K€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-03-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 67% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

ADMIT THERAPEUTICS

2.41M€ | Lider

DYMSA INGENIERIA

262.08K€ | Participante

SILIKEN MANUFACTURING

373.08K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ADVANCE-AD Novel biomarkers for improving diagnostics, prognostics, and... 3M€ Cerrado

SYSPHARMAD A systems pharmacology approach to the discovery of novel th... 1M€ Cerrado

MIRIADE Multi omics Interdisciplinary Research Integration to Addres... 4M€ Cerrado

MAP-AD A multimodal approach to accelerate drug discovery and devel... 258K€ Cerrado

FLUBIODEM Fluid Biomarkers for Neurodegenerative Dementias 2M€ Cerrado

BBDiag Blood Biomarker based Diagnostic Tools for Early Stage Alzhe... 3M€ Cerrado

Duración del proyecto: 43 meses Fecha Inicio: 2020-08-24
Fecha Fin: 2024-03-31

Líder del proyecto

ADMIT THERAPEUTICS Como actividad principal cnae 7211 investigacion y desarrollo experimental en biotecnologia. desarrollo de actividades de investigacion e in...

TRL 3-4 | 371K€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Each year an estimated 40M people suffer from Alzheimer’s disease (AD) globally, and a new case is diagnosed every 4 seconds, leading to a substantial socioeconomic burden of over €800B annually. Despite this large need, currently there is no cure available for AD. Moreover, the clinical trial failure rate for novel AD therapies being tested is over 99%. Every failed trial leads to large financial losses for the trial sponsor, and as a result there is an urgent need to reimagine AD clinical trial design. Recently, there has been a paradigm shift in the design of AD clinical trials, with most new trials now focusing on enrollment of Prodromal AD (P-AD) patients. However, patient recruitment in the P-AD stage is challenging as current methodologies (PET, MRI) lead to a large number of false positive and negative cases. As a result, optimal stratification of P-AD patients during clinical trial recruitment, remains an unmet market need. To meet this market need, ADmit Therapeutics, an innovative diagnostics SME, aims to deliver MAP-AD: an automated epigenetic analysis platform for accurate prediction of progression status of P-AD patients. The MAP-AD platform relies on novel machine learning algorithms that can identify specific methylation patterns in mitochondrial DNA (mtDNA) isolated from the blood samples of P-AD patients. This allows for a rapid and accurate selection of patients to be enrolled into a clinical trial independent of Aβ status, for the first time. During this EIC Accelerator project, we will finalize the development of our predictive algorithms together with a dedicated software interface, and perform clinical validation in collaboration with our hospital partners to deliver a finalized platform that is ready for commercial launch. We have a strong network of partners such as Bellvitge University Hospital, Hospital Clinic de Barcelona, CITA-Alzheimer, Hospital Moisès Broggi, Hospital General de l'Hospitalet, Janssen, Roche who will be the early adopters of MAP-AD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores